Understanding BPC-157 and Peptide Therapy BPC-157, short for Body Protection Compound-157 , is a synthetic peptide derived from a naturally occurring protein in human gastric juice
Research by Veni Bharti and colleagues has shown that individuals with MDD display reduced PUFA levels (146, 154), and that increasing dietary intake of unsaturated fatty acids (FAs), particularly PUFAs, has been linked to a decreased risk of depression (155157)
and Ida Green Professorship in System Biology (to J.Z.) from the UT Dallas
20 Similarly, A phase 2 trial of 320 patients with biopsy-confirmed MASH found that daily subcutaneous semaglutide (0.4 mg) achieved steatohepatitis resolution without fibrosis progression in 59% of patients vs
These are one of, if not the most rigorously studied class of peptides ever, with many large, placebo-controlled, randomized trials that followed over the past twenty years from the original GLP-1 drugs such as exenatide, approved by the FDA in 2005
They are complementary, not competitors
